Trulieve Brings Medical Cannabis Directly to Patients with Lake City’s First Dispensary

PR Newswire

The new dispensary marks the Company’s 67th location in Florida

TALLAHASSEE, Fla., Nov. 17, 2020 /PRNewswire/ – Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States, announced today the opening of a brand-new Florida dispensary, the Company’s 72nd nationwide. The new dispensary marks the first dispensary to open in Lake City, as well as the Company’s first in Columbia County.

The new dispensary supports Trulieve’s goal of expanding and ensuring direct, reliable patient access to medical cannabis across its home state of Florida. It joins the Company’s 66 other dispensaries statewide and brings a storefront to patients between Gainesville, Jacksonville, and Tallahassee.

“It’s always exciting to open the first dispensary in a new area like Lake City. Expanding medical cannabis access for patients in Lake City benefits those who have incorporated cannabis into their daily routines, and gaining new members of the community who may have been dissuaded from trying cannabis because of lack of access,” said Trulieve CEO Kim Rivers. “We thrive on the connection we’ve established with patients across the state and relish the opportunity to further connect directly with patients new and experienced throughout Columbia County.”

In honor of the Company’s brand-new dispensary, all patients — from those new to Trulieve to the dedicated Truliever community — will be eligible for a 25% in-store discount at the new Lake City dispensary on opening day. In line with policies adopted statewide, all visitors are required to wear masks for the duration of their dispensary visit. Additionally, only patients and their state-approved caregivers will be allowed inside the waiting room and dispensary at this time.

ANNOUNCING: Trulieve Lake City Grand Opening
WHERE: 2670 US Highway 90, Lake City, Florida 32055
WHEN: Wednesday, November 18, 2020, at 9:00 a.m.

In stores and online, patients will find Florida’s largest selection of THC and CBD products, available in a variety of delivery methods, including edibles, smokable cannabis, concentrates, tinctures, topical creams, vaporizers, and more. Trulieve also offers home delivery statewide for patients and convenient in-store pickup at each of its 67 dispensaries in Florida.

To assist patients with ordering, Trulieve has made our entire catalog of products available for online ordering, with in-store pickup and statewide home delivery options available. In addition, patients can schedule a complimentary 30-minute virtual consultation with a Trulieve certified consultant to help navigate questions on products, devices or to review their doctor’s recommendation. To learn more about consultations, click here to visit Trulieve’s website.

Furthermore, to assist with CDC recommendations for social distancing and in compliance with additional company-enforced safety guidelines, several measures have been taken to ensure the health and well-being of employees and patients, including modifications to the layout of all stores, installation of plexiglass partitions and HEPA air filtration scrubbers in every dispensary, increasing access to masks and sanitizer throughout the store for staff and visitors, utilizing visual aids to direct traffic throughout the store, and increasing the frequency of deep cleanings for all dispensaries.

Trulieve is closely monitoring the coronavirus situation and will update store policies as needed to ensure the safety of patients and staff. All updates will be shared directly on Trulieve’s website as they are enacted.

The Office of Medical Marijuana Use recently announced the registry was over 440,000 registered medical marijuana patients with an active ID card, with Trulieve consistently selling approximately half of the state’s overall volume per the Florida Department of Health. To support the state’s rapidly growing patient base, there are nearly 2,700 registered ordering physicians in the State of Florida.

For more information, please visit www.Trulieve.com.

About Trulieve 
Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also has operations in California, Massachusetts, Connecticut and Pennsylvania. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.

To learn more about Trulieve, visit www.Trulieve.com.

Cision View original content:http://www.prnewswire.com/news-releases/trulieve-brings-medical-cannabis-directly-to-patients-with-lake-citys-first-dispensary-301175145.html

SOURCE Trulieve Cannabis Corp.

ROSEN, A TOP RANKED LAW FIRM, Continues Investigation of Securities Claims Against Lendlease Corporation Limited – LLESY, LLESF

PR Newswire

NEW YORK, Nov. 17, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Lendlease Corporation Limited (OTC: LLESY, LLESF) resulting from allegations that Lendlease may have issued materially misleading business information to the investing public.

On November 9, 2018, Lendlease announced that it required a previously unannounced provision of AU$350M due to significant underperformance in its engineering division relating to a number of projects. On this news, Lendlease’s American depositary receipt (“ADR”) price fell over 24%, over the next full trading day, to close at $9.48 per ADR on November 12, 2018.

Then on December 19, 2019, the Sydney Morning Herald published an article entitled “Lendlease sells troubled engineering business to Spain’s Acciona” which described the sale as “Acciona will pay $180 million to Lendlease in a bargain basement price for the division beset with infrastructure projects weighed down with cost overruns and delays.” On this news, Lendlease’s ADRs fell almost 5% over the next three trading days, to close at $12.29 per ADR on December 23, 2019, damaging investors.

Rosen Law Firm is preparing a securities lawsuit on behalf of Lendlease shareholders. If you purchased securities of Lendlease please visit the firm’s website at http://www.rosenlegal.com/cases-register-1918.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-top-ranked-law-firm-continues-investigation-of-securities-claims-against-lendlease-corporation-limited–llesy-llesf-301175126.html

SOURCE Rosen Law Firm, P.A.

ReveraGen Receives $3.3 Million NIH Commercialization Readiness Pilot Grant for NDA Preparations for Vamorolone in Duchenne Muscular Dystrophy



— Funds will support NDA preparatory activities for anticipated filing in 2021 —

November 17, 2020, 08:30 AM Eastern Time

Rockville, Maryland—ReveraGen, Inc., a privately held company developing vamorolone (VBP15) as a potential safer alternative for corticosteroid treatment in Duchenne muscular dystrophy and other disorders, today announced an award of a $3.3 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) at National Institutes of Health (NIH). The two-year SBIR/STTR Commercialization Readiness Pilot (CRP) Program award will provide additional funding towards the new drug application (NDA) preparation, enabling timely filing after the read-out of the fully-enrolled registration study (VBP15-004; NCT03439670) anticipated in Q2 2021.

The Commercialization Readiness Pilot (CRP) program is designed to aid companies with previously funded SBIR/STTR Phase II/IIB projects as they advance to commercialization. ReveraGen has held a NINDS SBIR Phase II grant that enabled completion of Phase 2a clinical trials that showed dose-responsive improvement of vamorolone-treated DMD participants at both 24-weeks and 18-months treatment. A subsequent NIH SBIR Phase IIB award has supported the ongoing pivotal trial in 121 DMD boys recruited at 30 sites in 11 countries.

“This generous support from NIH is enabling the execution of the global regulatory and global intellectual property strategy of vamorolone, which we are developing jointly with Santhera,” said Dr. Eric Hoffman, VP Research and principal investigator at ReveraGen on the award.

“Upfront of the CRP application, ReveraGen had carried out a formal gap analysis to identify pending items required for the upcoming NDA submission, and the CRP award will be beneficial in addressing these,” noted Dr. Jesse Damsker, VP Operations at ReveraGen.

“We congratulate our partner ReveraGen to this grant which not only provides support in advancing vamorolone towards FDA submission and commercialization but also stands for recognition of the drug’s promising potential,” added Dario Eklund, Chief Executive Officer of Santhera.

ReveraGen has open INDs for development of vamorolone in both Duchenne muscular dystrophy and Becker muscular dystrophy. Studies of vamorolone in animal models of multiple chronic inflammatory diseases (multiple sclerosis, asthma, inflammatory bowel disease, arthritis and others) have shown efficacy similar to corticosteroids, and an improved safety profile. Studies of vamorolone in DMD boys have shown loss of the stunting of growth seen with treatment with corticosteroid standard of care (deflazacort, prednisone), with less physician-reported safety concerns.


Structure/activity studies
comparing the active metabolites of glucocorticoid receptor ligands (vamorolone, deflazacort, prednisone) have shown differential activity in binding co-activators and co-repressors, leading to vamorolone showing unique mechanisms of action. Specifically, vamorolone binding leads to less positive gene transcription activity associated with safety concerns, while retaining potent anti-inflammatory activity.

Recently, Santhera Pharmaceuticals has acquired a world-wide license to vamorolone in all indications. ReveraGen continues to manage the clinical programs and carry out NDA preparations.

About Vamorolone

Vamorolone is a first-in-class drug candidate that binds to the same receptor as corticosteroids but modifies its downstream activity and as such is a dissociative partial agonist. This mechanism has the potential to ‘dissociate’ efficacy from typical steroid safety concerns and therefore vamorolone could emerge as a promising alternative to existing corticosteroids, the current standard of care in children and adolescent patients with DMD. There is substantial unmet medical need in this patient group as high-dose corticosteroids have significant systemic side effects that diminish patient quality of life. The fully enrolled, pivotal Phase 2b VISION-DMD trial (VBP15-004, https://vision-dmd.info/2b-trialinformation ) is currently being conducted at study sites across North America, Europe, Israel and Australia and topline 6-month data are expected in Q2-2021, paving the way for a US NDA submission in Q4-2021. Vamorolone has been granted Orphan Drug status in the US and in Europe, and has received Fast Track and Rare Pediatric Disease designations by the US FDA and Promising Innovative Medicine (PIM) status from the UK MHRA. Vamorolone was discovered by US-based ReveraGen BioPharma, Inc. and is being developed in collaboration with Santhera, which owns worldwide rights to the drug candidate in all indications. The vamorolone development program has received funding from several international non-profit foundations and patient organizations, the US National Institutes of Health, the US Department of Defense and the European Commission’s Horizon 2020 program. See www.reveragen.com; https://vision-dmd.info.

About ReveraGen BioPharma

ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders. The development of ReveraGen’s lead compound, vamorolone, has been supported through partnerships with foundations worldwide, including Muscular Dystrophy Association USA, Parent Project Muscular Dystrophy, Foundation to Eradicate Duchenne, Save Our Sons, JoiningJack, Action Duchenne, CureDuchenne, Ryan’s Quest, Alex’s Wish, DuchenneUK, Pietro’s Fight, Michael’s Cause, and Duchenne Research Fund. ReveraGen has also received generous support from the US Department of Defense CDMRP, National Institutes of Health (NCATS, NINDS, NIAMS), and European Commission (Horizons 2020). www.reveragen.com.

Contact

ReveraGen BioPharma
Eric Hoffman, PhD, Vice President of Research
Phone: + 1 240-672-0295
[email protected]

 

Attachment



SoCalGas Supports LA Urban League’s Virtual Construction Training with $50,000 Grant – Company Hiring Up to 100 Qualified Graduates

Los Angeles Urban League & SoCalGas encourage Los Angeles residents interested in construction, mechanical, technician and engineering careers to apply to the free 10-week program

PR Newswire

LOS ANGELES, Nov. 17, 2020 /PRNewswire/ — Southern California Gas Co. (SoCalGas) today announced the company will provide a $50,000 grant to the Los Angeles Urban League (LAUL) to support the organization’s virtual Construction Career Academy (CCA) program. SoCalGas also plans to hire up to 100 qualified graduates of the program who progress through the company’s interview process. The Construction Career Academy is now accepting applicants to the no-cost, 10-week program on a rolling basis and encourages those interested in construction, mechanical, technician and engineering careers to apply.

“With many folks struggling to find work, now more than ever, the Construction Career Academy serves as a pathway to limitless opportunities in many different industries,” said Wallace Rawls, Director of Gas System Integrity & Programs at SoCalGas, and LAUL Board Member. “SoCalGas is proud to support the LA Urban League’s Construction Career Academy. We have been working with LAUL to develop pipelines for employment for graduates at SoCalGas and elsewhere, and we expect to hire some of the hardworking men and women who complete the program.”

“The Los Angeles Urban League thanks SoCalGas for the generous grant given to our Construction Career Academy. Our partnership with SoCalGas continues to reap benefits for the Construction Career Academy students,” said Michael Lawson, President, and CEO of the Los Angeles Urban League. “As we maintain our commitment to helping our constituents in Los Angeles’ underserved communities, we embrace and appreciate partners such as SoCalGas.”

“A quality career can change a life,” said 8th District Councilmember Marqueece Harris-Dawson. “The Los Angeles Urban League has long-served Los Angeles neighborhoods by educating and empowering communities of color through employment services. I remain committed to helping South LA residents access employment through local hire programs and I am pleased that SoCalGas is supplementing these efforts by investing in the Construction Career Academy, teaching Angelenos useful skills they can use for a lifetime.”

CCA provides a free 10-week training aimed at increasing minority workers’ access to apprenticeship programs and career opportunities in construction, mechanical, technical and/or engineering. The program prepares job seekers to complete and pass industry exams and go on to obtain apprenticeships and well-paying careers in a variety of industries including utilities, transportation, logistics, energy and building trades.

In addition to job sourcing and job placement, CCA also offers supportive services, job readiness skills and ongoing mentorship to support graduates in finding high-demand, well-paying jobs. Ninety percent of CCA graduates, who had little or no prior experience in construction or utility related positions, passed industry exams and found industry employment.

SoCalGas has been a longtime partner of the Los Angeles Urban League and the Construction Career Academy.

About SoCalGas

Headquartered in Los Angeles, SoCalGas® is the largest gas distribution utility in the United States. SoCalGas delivers affordable, reliable, clean and increasingly renewable gas service to 21.8 million customers across 24,000 square miles of Central and Southern California, where more than 90 percent of residents use natural gas for heating, hot water, cooking, drying clothes or other uses. Gas delivered through the company’s pipelines also plays a key role in providing electricity to Californians— about 45 percent of electric power generated in the state comes from gas-fired power plants.

SoCalGas’ vision is to be the cleanest gas utility in North America, delivering affordable and increasingly renewable energy to its customers. In support of that vision, SoCalGas is committed to replacing 20 percent of its traditional natural gas supply with renewable natural gas (RNG) by 2030. By developing renewable gas from our state’s abundant organic waste streams, we can help to meet our climate goals sooner, while diversifying our carbon-free energy sources, improving energy resilience and reliability, while also creating additional renewable fuel and jobs for our communities. SoCalGas is also committed to investing in its gas delivery infrastructure while keeping bills affordable for our customers. From 2014 through 2018, the company invested nearly $6.5 billion to upgrade and modernize its pipeline system to enhance safety and reliability. SoCalGas is a subsidiary of Sempra Energy (NYSE: SRE), an energy services holding company based in San Diego. For more information visit socalgas.com/newsroom or connect with SoCalGas on Twitter (@SoCalGas), Instagram (@SoCalGas) and Facebook. 

About Los Angeles Urban League

Los Angeles Urban League (LAUL) serves, educates and empowers African Americans and other minorities to secure economic self-reliance and civil rights by providing targeted social programs and advocating for issues that benefit our communities. The Los Angeles Urban League, founded in 1921, is a flagship affiliate of the National Urban League, founded in New York City in 1910. It is one more than 90 affiliates in the United States. The Los Angeles Urban League helps thousands of Angelenos annually through its programs focusing on education, entrepreneurship, job training and placement. Visit and follow the Los Angeles Urban League at laul.org.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/socalgas-supports-la-urban-leagues-virtual-construction-training-with-50-000-grant—company-hiring-up-to-100-qualified-graduates-301175140.html

SOURCE Southern California Gas Company

Waste Management Announces Cash Dividend

Waste Management Announces Cash Dividend

HOUSTON–(BUSINESS WIRE)–
Waste Management, Inc. (NYSE: WM) today announced the declaration of a quarterly cash dividend of $0.545 per share payable Dec. 18, 2020 to stockholders of record on Dec. 4, 2020.

ABOUT WASTE MANAGEMENT

Waste Management, based in Houston, Texas, is the leading provider of comprehensive waste management environmental services in North America. Through its subsidiaries, the Company provides collection, transfer, disposal services, and recycling and resource recovery. It is also a leading developer, operator and owner of landfill gas-to-energy facilities in the United States. The Company’s customers include residential, commercial, industrial, and municipal customers throughout North America. To learn more information about Waste Management, visit www.wm.com.

Waste Management

Website

www.investors.wm.com

Analysts

Ed Egl

713.265.1656

[email protected]

Media

Janette Micelli

602.579.6152

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Alternative Energy Energy Environment

MEDIA:

Logo
Logo

Del Taco is Ringing in the “Tamaledays” with a Limited-Time Tamale Menu, Fiesta Packs and Family Friday Deals All Season Long

Del Taco is Ringing in the “Tamaledays” with a Limited-Time Tamale Menu, Fiesta Packs and Family Friday Deals All Season Long

Del Taco is rolling out menu items like Cholula® Smothered Tamales, releasing exclusive wrapping paper, and planning surprise tamale deliveries to thank essential workers

LAKE FOREST, Calif.–(BUSINESS WIRE)–Del Taco Restaurants, Inc. (NASDAQ: TACO), the nation’s second largest Mexican quick service restaurant*, is saying “Happy Tamaledays” with a new slate of seasoned, shredded pork tamales. The festive, expanded menu lineup launches Thursday, November 19, 2020 and includes two tamales for $4, several smothered tamale options, such as Cholula® Smothered Tamales, and a Tamale Fiesta Pack for the whole family to enjoy.** Del Taco’s limited-edition Happy Tamaledays wrapping paper is also back by popular demand with two new custom designs available for purchase at the Del Taco webstore, while supplies last.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117006102/en/

Del Taco is saying “Happy Tamaledays” with a new slate of seasoned, shredded pork tamales. The festive, expanded menu lineup launches Thursday, November 19, and includes two tamales for $4, several smothered tamale options, such as Cholula® Smothered Tamales, and a Tamale Fiesta Pack for the whole family to enjoy. (Photo: Business Wire)

Del Taco is saying “Happy Tamaledays” with a new slate of seasoned, shredded pork tamales. The festive, expanded menu lineup launches Thursday, November 19, and includes two tamales for $4, several smothered tamale options, such as Cholula® Smothered Tamales, and a Tamale Fiesta Pack for the whole family to enjoy. (Photo: Business Wire)

Following an authentic, Mexican recipe, Del Taco’s tamales are made with seasoned, shredded pork and fire-roasted salsa, and surrounded by a layer of soft, stone-ground corn masa and wrapped in an authentic corn husk.

“Our authentic tamales are the perfect holiday comfort food, and this year you can make your hot tamale even hotter with Cholula® Hot Sauce,” said Tim Hackbardt, Del Taco’s Chief Marketing Officer. “We’ve also introduced our new Tamale Fiesta Pack that includes 12 tamales to feed the whole family or to stock up your fridge for a few days of meals with a simple trip through our convenient drive-thrus.”

Making tamales is a labor of love for many families over the holidays. Del Taco is embracing this tradition by surprising different groups of essential workers and deserving community members with free tamales every week in December excluding Christmas Day.

“The holidays may look a little different this year, especially for essential employees working long hours and making personal sacrifices to support their communities,” said Hackbardt. “The Del Taco family is on a mission to lift spirits and spread a little Tamaleday cheer this season, one tamale at a time.”

Tamaleday Celebrations – As part of the Tamaleday celebrations, fans can also score a different tamale menu item offer via the Del Taco app in December every Friday excluding Christmas Day with any purchase:***

  • Friday, December 4, 2020: Free Tamale with any purchase
  • Friday, December 11, 2020: $4 Off Tamales Fiesta Pack
  • Friday, December 18, 2020: $1 Off any Smothered Tamale Meal (Cholula, Red & Green, or Chili Cheese)

Download the Del Taco app to access Tamaledayoffers, and follow Del Taco on Instagram, Twitter and Facebook to join in the #Tamaledays celebrations.

Del Taco’s limited-time Tamales menu is available at participating locations starting November 19, 2020, and includes the following items:

  • Del Taco Tamales: Two for $4
  • Red and Green Smothered Tamales
  • Chili Cheese Smothered Tamales
  • Cholula® Smothered Tamales
  • Tamales Fiesta Pack: Includes12 tamales, Salsa Casera and utensils

*By number of units

**Available daily 10am to midnight while supplies last. Available for a limited time only. Single item price on menu board. Price and participation may vary. Delivery prices and fees may be higher.

***Offer available in the Del App. Registration required to access deals. Limit one offer per guest. Not valid with any other offer, discount or coupon. Price and participation may vary. Tamales available 10am to midnight in-store and 10am to 7pm for online ordering while supplies last, for a limited time only.

About Del Taco Restaurants, Inc.

Del Taco (NASDAQ: TACO) offers a unique variety of both Mexican and American favorites such as burritos and fries, prepared fresh in every restaurant’s working kitchen with the value and convenience of a drive-thru. Del Taco’s menu items taste better because they are made with quality ingredients like fresh grilled chicken and carne asada steak, sliced avocado, freshly grated cheddar cheese, slow-cooked beans made from scratch, and creamy Queso Blanco.

Founded in 1964, today Del Taco serves more than three million guests each week at its approximately 600 restaurants across 16 states. Del Taco’s commitment to providing guests with the best quality and value for their money originates from cooking, chopping, shredding and grilling menu items from scratch. For more information, visit www.deltaco.com.

Julie Colman

Largemouth Communications

919-459-6459

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Philanthropy Retail Restaurant/Bar Home Goods Other Philanthropy Food/Beverage

MEDIA:

Logo
Logo
Photo
Photo
Del Taco is saying “Happy Tamaledays” with a new slate of seasoned, shredded pork tamales. The festive, expanded menu lineup launches Thursday, November 19, and includes two tamales for $4, several smothered tamale options, such as Cholula® Smothered Tamales, and a Tamale Fiesta Pack for the whole family to enjoy. (Photo: Business Wire)

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bayerische Motoren Werke Aktiengesellschaft (BMWYY)

PR Newswire

BENSALEM, Pa., Nov. 17, 2020 /PRNewswire/ — Law Offices of Howard G. Smith reminds investors of the upcoming December 28, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Bayerische Motoren Werke Aktiengesellschaft (“BMW” or the “Company”) (OTC: BMWYY) securities between November 3, 2015 and September 24, 2020 inclusive (the “Class Period”).

Investors suffering losses on their BMW investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

On December 23, 2019, The Wall Street Journal reported that the U.S. Securities and Exchange Commission (“SEC”) was investigating whether BMW engaged in “sales punching,” a practice in which “a company boosts sales figures by having dealers register cars as sold when the vehicles actually are still standing on car lots.”

On this news, the price of BMW’s American Depositary Receipts (“ADRs”) fell $1.33, or nearly 7%, to close at $18.02 per ADR on December 23, 2019, thereby damaging investors.

On September 24, 2020, the SEC announced an $18 million settlement agreement with BMW regarding the investigation. According to the SEC’s order, from January 2015 to March 2017, the Company had “used its demonstrator and service loaner programs to boost reported retail sales volume and meet internal targets.” It also stated that from 2015 to 2019, BMW kept a reserve of unreported retail vehicle sales, which is used to meet internal monthly sales targets regardless of when the actual sale occurred.

On this news, BMW’s ADR price fell $0.51, or about 2%, to close at $23.07 per ADR on September 25, 2020, thereby damaging investors further.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) BMW kept a “bank” of retail vehicle sales that it used to meet internal monthly sales targets regardless of when the sales actually occurred; (2) BMW artificially manipulated sales figures by having dealers register cars as sold when the cars were still in inventory; and (3) BMW’s key operating metrics were inaccurate and misleading due to the forgoing facts. When the true details entered the market, the lawsuit claims that investors suffered damages; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired BMW securities, you may move the Court no later than December 28, 2020to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com

Cision View original content:http://www.prnewswire.com/news-releases/deadline-reminder-law-offices-of-howard-g-smith-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-bayerische-motoren-werke-aktiengesellschaft-bmwyy-301175094.html

SOURCE Law Offices of Howard G. Smith

Scott+Scott Attorneys at Law LLP Investigates Pfizer, Inc.’s (PFE) Directors and Officers for Breach of Fiduciary Duties

Scott+Scott Attorneys at Law LLP Investigates Pfizer, Inc.’s (PFE) Directors and Officers for Breach of Fiduciary Duties

NEW YORK–(BUSINESS WIRE)–Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Pfizer, Inc. (“Pfizer” or “Company”) (NYSE: PFE) breached their fiduciary duties to PFE and its shareholders. If you are a Pfizer shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or [email protected].

Scott+Scott is investigating whether Pfizer’s board of directors or senior management failed to manage Pfizer in an acceptable manner, in breach of their fiduciary duties to Pfizer, and whether Pfizer has suffered damages as a result.

On November 5, 2020, Pfizer disclosed that it had received an inquiry from the U.S. Securities and Exchange Commission’s (“SEC”) foreign-bribery unit, as well as informal requests for information from the SEC and the Department of Justice regarding the Company’s operations in China and Russia.

What You Can Do

If you are a Pfizer shareholder, you may have legal claims against Pfizer’s directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or [email protected].

About Scott+Scott

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, and Ohio.

Attorney Advertising

Joe Pettigrew

Scott+Scott Attorneys at Law LLP

230 Park Avenue, 17th Floor, New York, NY 10169

844-818-6982

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alibaba Group Holding Limited (BABA)

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alibaba Group Holding Limited (BABA)

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Alibaba Group Holding Limited (“Alibaba” or the “Company”) (NYSE: BABA) securities between October 21, 2020 and November 3, 2020 inclusive (the “Class Period”).

If you suffered a loss on your Alibaba investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/alibaba-group-holding-limited/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareho[email protected] to learn more about your rights.

Alibaba is an online and mobile commerce company. Alibaba owns a 33% equity interest in Ant Small and Micro Financial Services Group Co., Ltd. (“Ant Group”), a financial technology company that is best known for operating Alipay, one of the largest mobile and online payments platforms.

On July 20, 2020, Ant Group announced that it had begun the process of a concurrent initial public offering (“IPO”) on the Shanghai and Hong Kong stock exchanges.

On October 26, 2020, Ant Group priced its IPO and was set to raise $34.5 billion, making it the largest public offering in history.

On November 2, 2020, Financial Times reported that Chinese regulators had met with Ant Group’s controller Jack Ma, executive chairman Eric Jing, and Chief Executive Officer Simon Hu. The article stated that, though regulators did not provide details, “the Chinese word used to describe the interview – yuetan – generally indicates a dressing down by authorities.” The article also included a statement from Ant Group that it will “implement the meeting opinions in depth.”

On November 3, 2020, the IPO was suspended because Ant Group “may not meet listing qualifications or disclosure requirements due to material matters” related to the meeting with regulators the previous day and “the recent changes in the Fintech regulatory environment.”

On this news, the Company’s share price fell $25.27, or 8%, to close at $285.57 per share on November 3, 2020, on unusually heavy trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Ant Group did not meet listing qualifications or disclosure requirements for certain material matters; (2) that certain impending changes in the Fintech regulatory environment would impact Ant Group’s business; (3) that, as a result of the foregoing, Ant Group’s IPO was reasonably likely to be suspended; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Alibaba securities during the Class Period, you may move the Court no later than January 12, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles

Charles Linehan, 310-201-9150 or 888-773-9224

[email protected]

www.glancylaw.com

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)

LOS ANGELES, Nov. 17, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Innate Pharma SA (“Innate” or the “Company”) (NASDAQ: IPHA) securities between March 10, 2020 and September 8, 2020, inclusive (the “Class Period”).

If you suffered a loss on your Innate investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/innate-pharma-sa/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On October 23, 2018, Innate and AstraZeneca plc (“AstraZeneca”) announced an expansion of a pre-existing collaboration agreement, whereby AstraZeneca acquired 9.8% equity stake in Innate and obtained full oncology rights to monalizumab, a first-in-class humanized anti-NKG2A antibody.  As part of this agreement, Innate would receive $100 million in milestone payments at the start of the first Phase 3 clinical trial for monalizumab. 

On September 8, 2020, Innate announced that it had amended its collaboration agreement with AstraZeneca. Innate “will now receive a $50 million payment upon AstraZeneca’s dosing of the first patient in the Phase 3 trial, and a $50 million payment after the interim analysis demonstrates the combination meets a pre-defined threshold of clinical activity.” 

On this news, the Company’s American Depositary Share (“ADS”) price fell $1.62 per share, or 26.6%, to close at $4.45 per ADS on September 8, 2020.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Innate touted the results of their various Phase 2 trials as being within expectations; (2) Innate continued to reassure investors that they were eligible for the $100 million payment upon first dosing of Phase 3 trials; (3) Innate failed to timely disclose their renegotiations with AstraZeneca to split the $100 million payment into two $50 million payments, to be partially contingent on performance during the Phase 3 trials; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Innate securities during the Class Period, you may move the Court no later than December 22, 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. 

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com  
[email protected]